Blood markers for liver cancer before transplant
Part of Cancer, Digestive system clinical trials.
This study looks at two blood markers (AFP and PIVKA-II) in people getting a liver transplant for liver cancer. It aims to see if these markers can predict how well patients do after the transplant, which may help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with liver cancer (hepatocellular carcinoma) by an imaging test like CT or MRI, or by a biopsy.
- You must be planning to receive a liver transplant from a deceased donor for the first time.
- You must not have a blood clot in the main vein of the liver or other major blood vessel invasion.
- You must not have had a split or simultaneous transplant, or a re-transplant.
- You must not be taking warfarin (a blood thinner) when blood samples are taken.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people having liver cancer surgery. It will look at certain fats in your blood to see if they can help doctors understand and track liver cancer better.
This study uses a blood test (looking at sugars in the blood) to help predict whether liver cancer will come back after a liver transplant. It may help doctors monitor you more accurately and earlier if cancer returns.
This trial is testing if a blood test can find liver cancer early. It may help people who are newly diagnosed or suspected to have liver cancer and have not started treatment yet.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.